Eli Lilly’s Busiest Week: Vaccine Deals, a CVS Reversal, and a Supreme Court Setback

Eli Lilly closed the last week of May 2026 at €948.40 per share, nudging 2% lower on Friday as a Supreme Court ruling tempered the euphoria from a string of strategic wins. Yet the stock remains within striking distance of its 52-week high of €968.10, and the weekly narrative was anything but one-sided. In a span of five days, the company announced up to $3.83 billion in vaccine acquisitions, secured the return of its obesity drugs to CVS Caremark’s formulary, and absorbed a $220 million legal blow. The juxtaposition of these events underscores the breadth of forces shaping Eli Lilly’s trajectory as it juggles blockbuster growth in metabolic medicine with costly expansion into new therapeutic territory.

A $3.83 Billion Bet on Prevention

The most transformative move came midweek when Eli Lilly revealed its entry into vaccines through three separate transactions. The company will pay up to $1.5 billion for Curevo and its phase 2 shingles candidate Amezosvatein, up to $780 million for LimmaTech Biologics’ bacterial vaccine portfolio—including LTB-SA7 against Staphylococcus aureus—and up to $1.55 billion for a nanoparticle-based Epstein-Barr virus vaccine from an undisclosed company. The total outlay, financed from a cash chest largely filled by Mounjaro and Zepbound, marks a deliberate pivot from chronic disease management toward prevention. Analysts view the move as strategically coherent, even if it dilutes the pure metabolic narrative. Impfstoffe (vaccines) address a different care model, but the high-margin, multi-dose revenue streams fit Lilly’s long-term portfolio ambitions.

CVS Reopens the Door for Foundayo and Zepbound

On the commercial front, the more immediate catalyst arrived Friday. CVS Caremark, one of the three largest US pharmacy benefit managers, will restore coverage for Lilly’s obesity medicines after a roughly ten-month exclusion. The new oral GLP-1 drug Foundayo, which received FDA approval on April 2, 2026, lands on the standard formulary as of June 1, while the injectable Zepbound follows on October 1 as a peer option alongside Novo Nordisk’s Wegovy. With 25 to 30 million covered lives affected, the decision terminates a period dating back to July 2025 when patient groups had filed lawsuits over lack of access. CVS cited newly negotiated price cuts of 10% to 15% across the GLP-1 category as the rationale for the reversal. For patients with private insurance, monthly out-of-pocket costs will start at $25.

The move means all three major PBMs now cover Lilly’s entire obesity portfolio. That is commercially critical in the US, where reimbursement often dictates volume, especially for high-cost weight-loss therapies. Foundayo’s unique selling point—no strict food restrictions—should further boost patient uptake, and Lilly plans to present fresh cardiometabolic data at the upcoming American Diabetes Association congress.

Should investors sell immediately? Or is it worth buying Eli Lilly?

The Legal Headwind That Hardly Dents

The stock’s Friday dip of 2.03% was largely attributed to a US Supreme Court ruling that upheld a $220 million judgment against the company in a dispute over Medicaid rebates. The size is manageable for a firm that generated $19.8 billion in revenue last quarter alone, but it lands at a time when the shares are technically extended. The relative strength index sits at 72.4, and the stock is trading 15.6% above its 50-day moving average. Small setbacks can look outsized in such conditions. Still, market participants noted that the ruling does not alter the fundamental earnings trajectory.

Earnings Momentum and Pipeline Depth

Eli Lilly’s first-quarter 2026 results, released earlier, beat consensus comfortably. Adjusted earnings per share came in at $8.55, well above the $6.97 analyst estimate, while revenue surged 55% to $19.8 billion. Mounjaro alone contributed $8.7 billion, and Zepbound added $4.2 billion, cementing Lilly’s 60% share of the US GLP-1 market. Management now targets full-year revenue of $82 billion to $85 billion. On the pipeline front, the experimental triple agonist retatrutide is advancing through phase 3 studies, though physicians are monitoring side effects related to rapid muscle and bone density loss. A regulatory decision is not expected before 2027.

Options Activity, Split Chatter, and the Next Dividend

The derivative market reflected the week’s heightened interest. On Friday, nearly 47,000 call contracts changed hands, about 20% above the daily average. The median analyst price target stands at $1,227, with a consensus rating of “Moderate Buy.” At current levels, speculation about a stock split has resurfaced. Eli Lilly has not split its shares since the 1990s, and with the price flirting with quadruple digits, financial commentators debate whether 2026 could bring a split to improve accessibility for retail investors. The company has not confirmed any plans.

Eli Lilly at a turning point? This analysis reveals what investors need to know now.

Meanwhile, shareholders can look forward to a dividend payment of $1.73 per share on June 10. With support at $999.66 (in US trading) and resistance near $1,150, the technical setup remains bullish in spite of Friday’s hiccup. The confluence of a vaccine pivot, a pharmacy benefit win, and a manageable legal cost leaves Eli Lilly’s story richer and more complex—but the core earnings engine shows no sign of slowing.

Ad

Eli Lilly Stock: New Analysis - 30 May

Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Eli Lilly analysis...

en | US5324571083 | ELI | boerse | 69449234 |